Compare Bank of America Corp (BAC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of America Corp vs GeneDx Holdings Corp — how do they compare? Bank of America Corp trades at $60.85 (market cap $425.43B), while GeneDx Holdings Corp trades at $62.44 (market cap $1.85B). The key difference: Bank of America Corp is far larger — about 230× GeneDx Holdings Corp's market cap, and Bank of America Corp pays a 1.85% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| BAC | WGS | |
|---|---|---|
Market Cap | $425.43B | $1.85B |
Volume | 55,637,172 | — |
Sector | Financials | Technology |
52-Week High | $60.62 | $167.51 |
52-Week Low | $44.92 | $34.51 |
Dividend Yield | 1.85% | — |
Enterprise Value | — | $1.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of America (BAC) trades at $60.62, up 1.59% today, with a bullish technical signal from moving averages and a consensus analyst price target of $63.79. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $1.11 exceeding expectations. Revenue grew to $113.10 billion in 2025, and the company maintains a strong deposit franchise, as highlighted by recent news coverage.
The outlook is positive, supported by earnings momentum and potential capital returns post-stress tests. Risks include macroeconomic sensitivity and regulatory changes. Analyst sentiment is strongly bullish, with 65% recommending Buy.
GeneDx Holdings (WGS) trades at $63.85, down 2.73% amid multiple securities class action lawsuits alleging misleading acquisition performance disclosures. The stock shows bearish technical signals with support at $60 and resistance at $65. Fundamentally, the company reported negative net income of -$21.02M for 2025 despite revenue growth to $427.54M, with profitability metrics deteriorating significantly in 2026 projections.
Despite 91% analyst buy ratings and a $75.40 consensus target, substantial legal risks and negative earnings momentum create significant headwinds. The stock faces near-term pressure from litigation while long-term viability depends on reversing negative margin trends and resolving acquisition-related impairment issues that triggered the 49% stock decline cited in lawsuits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of America Corp
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
